Skip to content
Open access

Comparative Metagenomics of the Gut Microbiome in IBD vs IBS Patients

Sep 2026 · International Journal of Drug Delivery Technology · 0 citations

Abstract

Background: Inflammatory bowel disease and irritable bowel syndrome commonly present with overlapping gastrointestinal symptoms but differ substantially in their underlying mechanisms. Objective: To compare the gut microbiome composition and functional metagenomic profiles of patients with inflammatory bowel disease and irritable bowel syndrome. Methodology: This comparative cross-sectional study was conducted at Allama Iqbal Teaching Hospital, Dera Ghazi Khan from June 2024 to June 2025 and included 170 patients equally divided into inflammatory bowel disease (n=85) and irritable bowel syndrome (n=85) groups. Results: The inflammatory bowel disease group had significantly higher mean C-reactive protein (18.6 ± 9.5 vs. 4.2 ± 2.1 mg/L), erythrocyte sedimentation rate (32.4 ± 13.7 vs. 13.8 ± 6.5 mm/hour), and fecal calprotectin levels (416.8 ± 154.6 vs. 64.3 ± 32.8 µg/g) than the irritable bowel syndrome group; all p<0.001. Microbial diversity was significantly lower in inflammatory bowel disease, with reduced Shannon (3.28 ± 0.64 vs. 4.12 ± 0.58) and Simpson indices (0.73 ± 0.09 vs. 0.84 ± 0.07); both p<0.001. Patients with inflammatory bowel disease had lower Firmicutes abundance (36.8 ± 10.4% vs. 49.7 ± 11.3%) and higher Proteobacteria abundance (21.4 ± 7.8% vs. 9.3 ± 4.5%); both p<0.001. Conclusion: It is concluded that inflammatory bowel disease is associated with markedly reduced microbial diversity, depletion of beneficial bacteria, enrichment of pro-inflammatory taxa, and altered microbial metabolic pathways compared with irritable bowel syndrome.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.